A Key Test For Genetic Testing

This has been a banner year for Mark H. Skolnick. Last fall, a team led by the University of Utah geneticist beat out 12 others in an epic battle to find a key gene that is implicated in up to 10% of all cases of breast cancer. Then, on Oct. 6, Skolnick's company, Myriad Genetics Inc., went public at $18 a share, and the stock has since almost doubled. As co-founder and executive vice-president for research, Skolnick holds a 12% stake in Myriad that is now worth $22 million.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.